Cocrystal Pharma (NASDAQ:COCP) Shares Down 1.9% – Time to Sell?

Shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) dropped 1.9% on Friday . The company traded as low as $1.0304 and last traded at $1.04. Approximately 13,569 shares were traded during mid-day trading, a decline of 86% from the average daily volume of 99,907 shares. The stock had previously closed at $1.06.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cocrystal Pharma in a report on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $6.00.

Cocrystal Pharma Price Performance

The business’s 50-day moving average is $1.03 and its 200 day moving average is $1.26. The firm has a market capitalization of $14.34 million, a P/E ratio of -1.11 and a beta of 1.13.

Cocrystal Pharma (NASDAQ:COCP) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.03. Analysts anticipate that Cocrystal Pharma, Inc. will post -1.85 EPS for the current fiscal year.

Insider Activity

In related news, Director Phillip Md Et Al Frost bought 50,000 shares of Cocrystal Pharma stock in a transaction dated Wednesday, December 31st. The shares were bought at an average cost of $0.95 per share, with a total value of $47,500.00. Following the acquisition, the director owned 1,838,551 shares in the company, valued at $1,746,623.45. This trade represents a 2.80% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Over the last quarter, insiders acquired 159,000 shares of company stock worth $152,710. Corporate insiders own 28.14% of the company’s stock.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.